These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29594215)

  • 1. Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer.
    Holmes OE; MacRae R; Cook G; Cross P; Nair V; Marginean H; Pantarotto JR
    Clin Transl Radiat Oncol; 2017 Aug; 5():37-41. PubMed ID: 29594215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
    Lee IH; Chen GY; Chien CR; Cheng JC; Chen JL; Yang WC; Chen JS; Hsu FM
    J Formos Med Assoc; 2021 Dec; 120(12):2176-2185. PubMed ID: 33451864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer.
    Dreyer J; Bremer M; Henkenberens C
    Radiat Oncol; 2018 Nov; 13(1):213. PubMed ID: 30390700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer.
    Kopek N; Paludan M; Petersen J; Hansen AT; Grau C; Høyer M
    Radiother Oncol; 2009 Dec; 93(3):402-7. PubMed ID: 19559492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
    Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
    Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation.
    Simon TG; Beland MD; Machan JT; Dipetrillo T; Dupuy DE
    Eur J Radiol; 2012 Dec; 81(12):4167-72. PubMed ID: 22835876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy.
    Fink CA; Weykamp F; Adeberg S; Bozorgmehr F; Christopoulos P; Lang K; König L; Hörner-Rieber J; Thomas M; Steins M; El-Shafie RA; Rieken S; Bernhardt D; Debus J
    Clin Transl Radiat Oncol; 2023 Sep; 42():100665. PubMed ID: 37564923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
    Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
    Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H; Mahmood S; Rajashanker B; Shah R
    Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of the Age-Adjusted Charlson Comorbidity Index Among the Elderly with Breast Cancer.
    Wang Z; Zhong Y; Zhou Y; Mao F; Zhang X; Wang C; Sun Q
    Clin Interv Aging; 2023; 18():1163-1174. PubMed ID: 37525754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
    Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.
    Agarwal JP; Pilar A; Mummudi N; Gupta M; Laskar SG; Pathak RS; Tibdewal AR; Kinhikar R; Ghadi Y; Tandon S; Purandare N; Prabhash K; Patil V
    Indian J Cancer; 2020; 57(1):18-24. PubMed ID: 31929233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
    Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
    Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-adjusted Charlson Comorbidity Index predicts prognosis of laryngopharyngeal cancer treated with radiation therapy.
    Takemura K; Takenaka Y; Ashida N; Shimizu K; Oya R; Kitamura T; Yamamoto Y; Uno A
    Acta Otolaryngol; 2017 Dec; 137(12):1307-1312. PubMed ID: 28875745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience.
    Hobbs CJ; Ko SJ; Paryani NN; Accurso JM; Olivier KR; Garces YI; Park SS; Hallemeier CL; Schild SE; Vora SA; Ashman JB; Rule WG; Bowers JR; Heckman MG; Diehl NN; Miller RC
    Mayo Clin Proc Innov Qual Outcomes; 2018 Mar; 2(1):40-48. PubMed ID: 30225431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.